Improved Retinal Drying and Treatment Durability In nAMD Qith Aflibercept 8mg

Now Viewing

EP: 1.Improved Retinal Drying and Treatment Durability In nAMD Qith Aflibercept 8mg

EP: 2.Rapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights

Video content above is prompted by the following:

The first episode discusses case-based roundtable findings from retina specialists and residents regarding neovascular age-related macular degeneration (AMD) treatment. Dilsher S. Dhoot, MD​from California Retina Consultants presents multiple cases showing the efficacy of second-generation anti-VEGF therapies. The first case highlights a patient with persistent subretinal fluid despite bevacizumab treatment who showed improvement after switching to aflibercept 8mg, demonstrating both improved durability and efficacy with treatment intervals extending to 8 weeks.

A second case presents a patient with bilateral neovascular AMD and pigment epithelial detachments (PEDs) who responded exceptionally well to aflibercept 8mg in both eyes, achieving near-resolution of PEDs and complete resolution of intraretinal fluid. The panel discussed different treatment approaches, with some physicians preferring three loading doses before extension while others treated to dryness before immediately extending treatment intervals. The importance of discussing RPE tear risks with patients having large PEDs was emphasized.

Additional cases demonstrated aflibercept 8mg's effectiveness in patients with suboptimal responses to first-generation therapies. One patient with a fibrous PED and subretinal fluid showed marked improvement after switching from bevacizumab to aflibercept 8mg, with vision improving from 20/100 to 20/50. The final case illustrated that while some patients respond well to first-generation therapies like aflibercept 2mg, careful monitoring is necessary as durability may be limited with reactivation of subretinal fluid requiring consistent treatment.